Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 11/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514016 | 0.92 | IDH1 (0.36) | HSD11B1IDH1HRH3P2RX7 | |
| SCHEMBL4515140 | 0.81 | HSD11B1 (0.45) | HSD11B1HRH3LIPGP2RX7 | |
| SCHEMBL13675575 | 0.79 | KDM4E (0.37) | HSD11B1 | |
| SCHEMBL4519281 | 0.78 | HSD11B1 (0.53) | HSD11B1HRH3LIPGP2RX7FFAR4 | |
| SCHEMBL4522654 | 0.77 | HSD11B1 (0.49) | HSD11B1HRH3LIPGP2RX7 | |
| SCHEMBL13674510 | 0.76 | ALDH1A1 (0.38) | P2RX7 | |
| SCHEMBL13675467 | 0.76 | HSD11B1 (0.39) | HSD11B1P2RX7 | |
| SCHEMBL4510247 | 0.76 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL13674513 | 0.74 | HSD11B1 (0.40) | HSD11B1P2RX7 | |
| SCHEMBL4510197 | 0.74 | OPRM1 (0.39) | HSD11B1P2RX7FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885IDH1 278/4885HRH3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.